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This guidance is written to 
assist clinicians working in 
prisons but it also has relevance 
for clinicians working in other 
secure environments. It will be 
of use to prescribers working in 
the community whose patients 
regularly have periods in custody 
or when a patient is expecting a 
custodial sentence. Community 
clinicians should be aware of 
important prescribing issues in 
the prison system when patients 
enter custody. Rationalisation of a 
patient’s care before detention may 
help the transition into custody and 
the care provided by the prison 
healthcare team. Other clinicians 
who may find the guidance a 
useful reference are: forensic 
physicians and custody nurses; 
consultant psychiatrists; pain clinic 
prescribers; hospital prescribers.
Purpose of this Guidance:
The authors of this guidance are members of the Royal College of 
General Practitioners Secure Environments Group. Where possible 
NICE and Offender Health guidance is followed. Where necessary, 
to improve upon safety and security within prisons, this guidance 
has been adapted to meet the needs of the environment and the 
population it confines. It aims to maintain equivalence of effect, 
equivalence of practice and equivalence of outcome wherever 
possible. In doing this a consensus approach, utilising experience 
gained from working within the environment has been employed.
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Introduction
There are 136 prisons in England. 
Their primary purpose is to detain 
in custody individuals proven 
or suspected of committing a 
criminal offence. This means that 
at any one time more than 80,000 
individuals are confined to custody 
and approximately 140,000 people 
move through the prison system 
each year. Whilst detained, the 
majority of these individuals have 
health needs. It is the responsibility 
of many separate healthcare teams 
to meet these needs. 
As part of the process that seeks to treat ill health and promote 
healthier living and the greater wellbeing of patients that are treated 
within prisons, pharmacotherapy and therefore the prescribing of 
medication plays an important role. Many prisoners, though not all, 
are accustomed to using illicit and prescribed drugs to ameliorate 
or treat symptoms and perceived wants and needs. They may not 
have considered or tried other types of therapy to improve health 
and wellbeing. Time spent in custody can be used to encourage 
prisoners to change their lifestyle and the use of non-drug therapies 
can challenge the over-reliance on pharmacological treatment.
Medications are misused within prisons. Therefore, medications that 
may be misused present particular problems within prisons and the 
wider realm of secure environments as well as in the community.
Within prisons a significant proportion of patients will seek 
prescribed medication for the psychotropic effect rather than its 
therapeutic or licensed use. Many of these patients will have a 
previous history of substance misuse. Prescribing medication where 
there is no clinical indication is clearly inappropriate and clinicians 
who prescribe in prisons should understand that medications 
may be misused. They acquire a commodity value and are often 
traded within prisons. The acquisition, misuse and onward trading 
of prescribed medication cannot be supported and should be 
discouraged as it presents risks in many ways.
Primarily it presents a risk to the individual who is misusing a 
prescription medication. Misusing multiple medications increases the 
potential harm to that person. Some treatments may be prescribed 
to the individual and others may be acquired from the illicit economy 
within prisons presenting significant risks of harm through overdose 
and interaction. 
The diversion of prescribed medication to the illicit economy 
that exists also presents risk to the wider prison environment as 
individuals, groups and gangs within prisons continue in behaviours 
that may put the safety of other individuals at risk. That risk may 
come in the form of bullying and threats of assault as an individual 
is intimidated into diverting a medication prescribed appropriately 
to them. This coercion may force an individual to divert their 
medication. They will therefore not receive their own prescribed 
medication which may have a direct health consequence and that 
medication could be diverted into the illicit economy, thus presenting 
risk to the wider prison population. 
The trading of prescribed medications also puts individuals at 
risk through the accumulation of debt and this debt may cause 
significant risk to personal safety and may also impact on a patient’s 
physical and mental health.
Methods of diversion of medication are varied 
and the risk of diversion is mitigated by limiting 
the amount of medication that a particular 
establishment would allow the patients to keep 
‘in possession.’ Medication is usually dispensed 
supervised by individual dose, daily, weekly, 
monthly or at other recognised intervals depending 
upon the type of drug, patient factors and security 
factors within the prison. Some medication is 
administered in a supervised manner in prisons.
Within certain types of prisons (Local remand 
prisons, Category A and B establishments) a 
significant proportion of the medication prescribed 
is administered at pre-set times via centralised 
or wing based dispensaries. This is usually when 
diversion occurs and may take the form of simply 
pocketing medication or doses may be concealed 
within the mouth and be removed later and sold. 
Sometimes medication is regurgitated as in the 
case of ‘spit methadone’ and there have been 
reports of saliva being dried to allow the diversion 
of sublingual preparations of particular medicines 
to enter the illicit economy. Prescribers should 
not use ‘daily in possession’ packs where there 
is significant risk of diversion, and as a means of 
preventing self-harm they offer only marginal benefit 
over ‘weekly in possession’ supply.
Considering these issues, clinicians who work 
within prisons should be aware of patients 
presenting with exaggerated or fictitious disorders 
in an attempt to gain a prescription for a medication 
they do not require with an intent to divert this 
medication into the illicit economy of the prison. 
Clinicians who choose to work within prison 
should also be familiar with the requirement of 
mandatory testing of prisoners for drugs and they 
should consider whether their prescriptions could 
mask illicit drug use, particularly with regard to the 
prescribing of opiates.
Since the responsibility to commission health 
care services within prisons transferred to PCTs 
in April 2006, there have been improvements in 
the quality of the services delivered within prisons. 
The standard of care should be equivalent to 
the standard that is delivered in the community. 
This equivalence is fundamental, but equivalence 
does not imply ‘sameness.’ Prisons are complex 
environments with challenging populations and in 
providing equivalence some areas of health delivery 
should be adapted to mitigate risk. The choice 
of medication is one area where clinicians who 
work within prisons should consider equivalence 
carefully. It is appropriate that this occurs as the 
clinician has responsibilities, not only to the patient, 
but to the wider prison community. They have a 
responsibility, through prescribing appropriately for 
the environment in which they work, to reduce risks 
to the wider prison population. 
The specific detail of how a prison seeks to reduce 
the inherent risks with medication use and abuse 
within its confines should be decided on a prison 
by prison basis. It should be inclusive of Prison 
Service Orders and Instructions, and it should also 
reflect the category of the prison itself. Further to 
this, the nature and behaviours of the population 
that the prison confines should be taken into 
account. Engagement with the Drug Strategy Team 
at the prison to understand the local issues can 
provide a co-ordinated approach to mitigating risk. 
The clinical governance of prescribing policy should 
be overseen by the commissioning organisation.
When an individual treatment is being determined, 
decisions should be individualised to the patient so 
that the particular need of the patient is met, while 
the duty to reduce risk to the prison population is 
fulfilled.
The principles for mitigating this risk are not 
complicated but they may incur additional costs. 
The increased cost of providing services within 
a secure environment may be an appropriate 
expenditure for a healthcare provider to undertake 
and this should be recognised within prescribing 
budgets. The involvement of a pharmacist 
experienced in secure environment practice can 
optimise risk mitigation and ensure cost-effective 
use of the most appropriate pharmaceutical form of 
medication.
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The principles of reducing the risks of medications 
are choice of preparation; form of the preparation; 
use of an alternative; and occasionally the use 
of an unlicensed medicine. The GMC recognises 
that in certain situations doctors prescribe 
unlicensed and off-label preparations where good 
evidence exists of their benefit and their use in 
the particular circumstances can be justified. 
Injectable preparations when administered do not 
get diverted and they ensure compliance. Therefore 
depot medications may be an option in certain 
circumstances.
The change of preparation from a standard release 
tablet based medication to a modified release 
tablet or even a liquid based medication reduces 
the potential for diversion. Capsules may cause 
problems as the medication comes in a form that 
is readily diverted, the capsule opened and the 
powder or granular contents may be injected or 
snorted.
In the following pages, the most common 
medications misused within prisons are considered 
and rated for their general suitability for use 
within a secure environment. There are of course 
local circumstances which may override these 
recommendations. This guidance does not deal 
specifically with the integrated treatment of drug 
users or the management of palliative care in 
prisons. The authors have used a traffic light 
system to evaluate medicines, with regard to the 
risk of use in this environment.
Red medicines 
are generally considered to be  inappropriate in prisons as their misuse potential and their potential 
for harm is considered unacceptable and alternative medications are available. They carry the 
highest risk if used and they should only be considered where alternatives are not available.
Amber medicines 
should usually only be considered as a treatment when other choices are inappropriate or have 
been used unsuccessfully. Even in this circumstance they should be prescribed with caution. 
Amber medications have a recognised abuse potential and experience from the prison estate 
supports the assumptions that these medications are abused in practice. Their abuse should 
not be supported but the risk of individual harm is arguably less than the red category. For a 
prison population as a whole though, the risk associated with widespread trading may not be 
reduced and widespread use of amber medications should be considered as inappropriate 
within a particular prison. In limited circumstances amber medications may be prescribed as first 
line treatments but their potential for abuse remains high. An example of this is benzodiazepine 
withdrawal treatment.
Green medications 
carry lower risk and where possible after assessing individual need and prison factors these 
medications would generally be a first choice treatment. To facilitate these medications as first 
choice treatments, they may need to be used off licence or outside of NICE guidance.
It should be noted, that in balancing the risks 
of the environment and the risks of a particular 
medication against the needs of an individual, it 
may be appropriate to prescribe a medication that 
is outside of accepted community guidance and 
practice. It is defensible and appropriate to do 
this in circumstances where equivalence of care 
is being sought, having carefully considered and 
documented this risk evaluation.
This guidance identifies the most problematic drug 
groups and preparations. It considers some of the 
key issues and links these to national guidelines 
and evidence to support prescribing decisions.  
The guidance is intended for all prescribers 
working within prisons, particularly those with 
less experience of this specialist area of practice.  
The guidance will also be of value to primary care 
prescribers in the community who provide care 
for patients with addiction and forensic problems 
and also to those prescribers in secondary care 
where, either on an out-patient or in-patient basis, 
their patients will return to a custodial setting. The 
guidance does not include every preparation in a 
class nor should it be regarded as exhaustive in 
covering every prescribing issue related to the drug 
groups.
Additional Resources
This document updates and enhances advice given on the NELM website in 2008. 
Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in 
adults. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD007938 
http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Drug-Specific-Reviews/Gabapentin-for-chronic-neuropathic-
pain-and-fibromyalgia-in-adults/ [accessed 20 July 2011].
Royal Pharmaceutical Society. British National Formulary. London: British Medical Association and the Royal 
Pharmaceutical Society, 2011.  
http://bnf.org/bnf/index.htm [accessed 04 July 2011].
ECG monitoring
Royal College of Psychiatrists. Consensus statement on high-dose antipsychotic medication 
Approved by Council: October 2005. Due for review: 2008 Council Report CR138. London: Royal College of 
Psychiatrists, May 2006. 
http://www.rcpsych.ac.uk/publications/collegereports/cr/cr138.aspx [accessed 04 July 2011].
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Possession of Medicines
In June 2003, as part of a wider 
programme to bring improvements 
in health care delivery to prisoners, 
HM Prison Service and the DH 
(Department of Health) jointly 
published ‘A Pharmacy Service 
for Prisoners’. Recommendation 5 
states:  
‘Medicines in use, together 
with associated monitoring and 
administration devices, should 
normally, as a matter of principle, 
be held in the possession of 
prisoners. Each prison should 
have a policy and risk assessment 
criteria, developed through the 
Drug and Therapeutics Committee, 
for determining on an individual 
basis when medicines and related 
devices may not be held in the 
possession of prisoners’.
In addition, Prison Service Order 
3550 and PSI 45/2010 require that: 
‘All drugs liable to misuse within 
the prison setting must be 
administered under supervised 
conditions’.
Many drugs with central nervous 
system effects are sought by 
prisoners with a history of drug 
taking or chronic drug misuse.  
Prescribers should be aware 
that they may be manipulated to 
prescribe these drugs where there 
is not a genuine indication. In addition, prisoners with an identified 
need receiving these drugs may be bullied to divert the drug to 
others. Prisoners should be risk-assessed and regularly reviewed 
to ensure that they receive their medication in the most appropriate 
way for the safety of the individual and the safety of the wider prison 
community.
All prisons are expected to have a local policy regarding medication. 
That policy should follow national guidance but be localised to 
the specific establishment and the nature of the population that 
if confines. The aim of that policy is to form a balanced approach 
respecting the autonomy of the individual patient and promoting 
that autonomy in the context of patient safety. Such medicines 
management policy also forms a method through which individual 
prisons can demonstrate the mitigation of risk in respect to both 
health service provider and establishment.
When prescribers are considering an appropriate form or dosage 
regimen of medicine for those patients who have been risk assessed 
to receive their medication ‘Not In Possession’, they will need to 
take into account the restrictions of the custodial regime with regard 
to timing of dosing, availability of medicine administration times and 
other factors that may affect their choice. Use of modified release 
preparations that require once or twice daily dosing can ensure 
optimal treatment is provided with reduced risk. The pharmacist is a 
useful resource for finding out the range of preparations available. 
References
Department of Health/HM Prison Service. A Pharmacy Service for 
Prisoners. London: Department of Health, 2003. http://www.dh.gov.
uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/
digitalasset/dh_4065707.pdf [accessed 01 July 2011].
National Prescribing Centre (NPC). Medication In Possession.  
A guide to improving practice in Secure Environments. Liverpool, 
NPC, 2005.  
http://www.bulger.co.uk/prison/Pharmacy_in_possession_guide.pdf 
[accessed 01 July 2011].
HM Prison Services. Clinical Services for Substance Misusers. 
Prison Service Order (PSO) 3550. London: HMPS, 2001. 
http://www.hmprisonservice.gov.uk/resourcecentre/psispsos/
listpsos/ [accessed 01 July 2011].
HM Prison Services. Integrated Drug Treatment System. PSI 
45/2010. London: HMPS, 2010. 
http://www.hmprisonservice.gov.uk/resourcecentre/psispsos/
listpsis/ [accessed 01 July 2011].
Within prisons the incidence of 
patients requesting treatment 
for pain is high and clinicians 
who issue these prescriptions 
should be aware of the abuse 
potential of prescription drugs. 
Clinicians should be acutely aware 
of the problems associated with 
analgesia abuse and dependence. 
The main area of concern is opiate 
based analgesia.
It is not appropriate to fully exclude 
the use of weak and strong opiates 
as this would encourage over 
reliance on non steroidal anti-
inflammatory drugs which carry 
their own risks of use and without 
recourse to opiate medication 
patients may be left with genuine 
pain that is under treated. However 
consideration must be given to 
the addiction potential of opiates, 
particularly in those patients with a 
tendency to addictive behaviours.  
Opiate analgesia should be 
prescribed for as short a period 
as possible. It is noteworthy that 
despite initial guidance that tramadol 
was safer and less addictive than 
existing opiates, post marketing 
evidence now shows that the 
drug possesses similar risks to the 
more traditional opiates, and also 
additional risks relating to its effect 
on other biochemical receptors.
Pain
The use of opiate based medication is particularly problematic within 
prisons as access to stronger illicit opiates is reduced to a certain 
degree. Although one would reasonably assume that the expansion 
of substitute prescribing across the prison estate would eradicate 
or minimise this, experience shows that despite opiate substitution 
prescribing, opiate medication abuse, particularly but not exclusively, 
in the form of prescribed weaker opiates is still common place. 
Dihydrocodeine, codeine and tramadol are misused both for their 
euphoric potential and their sedative effect and are very popular 
with heroin users, as they also alleviate opiate withdrawal. As 
these medications have well recognised abuse potential, they have 
acquired significant commodity value within many prisons and their 
diversion and misuse puts vulnerable individuals at risk of coercive 
diversion. Clinicians who work within a prison should therefore be 
mindful of the risks to the wider prison population when prescribing 
opiate based analgesia whilst discharging their duty of care to a 
particular patient who is expressing pain symptomology. These 
preparations are widely misused throughout society.
This risk to the wider prison population is reflected within prison 
service orders/ instructions. PSO 3550 and PSI 45/2010 require that 
medicines subject to abuse should not be held in possession within 
prison, and clinicians can mitigate the risk further by consideration 
of medication formulation when the prescription of an opiate based 
analgesia is considered appropriate. An example of this would be 
the prescription of soluble or effervescent medications to reduce 
the risk of diversion at supervised consumption. Mitigating risk by 
offering alternative formulations of the same medicine does carry 
cost implications and this should not form an undue barrier to 
providing a specific medication where other alternatives are not 
available. Soluble opiates may be less suitable in patients with 
hypertension and heart disease because of the high sodium content.
Specific consideration should be given to the appropriateness of 
prescribing opiate based medication within a consultation and 
whether an alternative medication or adjuvant could be utilised for 
an individual presentation of a patient. Whilst not advocating under-
treating genuine pain, clinicians should be aware that expressing 
symptoms of pain is one method of eliciting opiates for misuse and 
the assessment of reported pain should be the subject of continuous 
rigour from the clinician. In providing an opiate prescription a clinician 
may be initiating, legitimising or facilitating an opiate dependency.
Prescribed opiates may also be used to mask the continued use of 
illicit opiates and therefore confound systems used by a prison such 
as mandatory drug testing in reducing illicit drug use. 
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Clinicians should actively avoid the perception of 
collusion with a patient whilst maintaining treatment 
that is appropriate to the environment and in the 
patient’s best interests.
Dihydrocodeine has historically been used within 
prisons as a detoxification agent and in police 
custody as symptomatic treatment. It still maintains 
strong associations in prisons with the substance 
misusing population. It is generally an inappropriate 
analgesic where individuals have a history of 
substance misuse even if an individual has entered 
recovery. Individual establishments should consider 
via their medicines management committees 
whether dihydrocodeine should be within the prison 
medication formulary and this decision should 
reflect the nature of the population that the prison 
confines.
With increasingly ageing populations detained 
within prisons, analgesic patches are being used 
to control chronic and cancer based pain with 
increasing frequency. The use of these patches 
presents the clinician with further considerations 
as prison health care providers have experienced 
patients abusing the analgesic patch through 
‘sharing’ the patch with others. Therefore checking 
the site of the patch may be considered as a 
method of monitoring risk and patches can 
be covered with secondary dressing to help 
maintain their security. The Summary of Product 
Characteristics must be checked for the individual 
product if this is being considered to ensure that 
this practice is not known to affect the absorption 
profile of the patch. Additionally, patches which 
are non matrix patches and therefore contain 
a reservoir of strong opiate medication are not 
appropriate for use within secure environments as 
diversion of the liquid presents a significant risk to 
individuals.
The use of novel delivery methods of strong 
opiates, such as ‘lollipops,’ presents a significant 
risk of abuse within prisons. The patient to whom 
this formulation of medication is prescribed may 
be at risk of bullying. When recommended by a 
consultant, their use within prisons should always 
be within a comprehensive support and security 
package to minimise the risk to an individual who 
would normally be considered vulnerable as a 
consequence of a disease process. The use of 
‘lollipops’ is discouraged and the use of alternative 
analgesia delivery methods advocated. It can be 
helpful to discuss with pain clinic consultants the 
significance of their choice of analgesic product as 
they may be unaware of the implications within a 
secure environment.
The management of acute pain within prisons may 
also lead to prescription medication dependency 
if treatment plans are not specific, documented 
and adhered to. All prescriptions of opiate based 
medication should be subject to regular review to 
determine whether the continued prescription is 
appropriate. In the case of chronic pain, clinicians 
may consider the planned use of opiate holidays 
with suitable alternative analgesia to help minimise 
the possibility of prescription opiate dependence.
Tramadol is licensed for moderate to severe 
pain but is not as effective as strong opioids for 
severe pain being roughly equivalent to codeine 
in strength. Nausea, dizziness and constipation 
are common side effects (although nausea and 
constipation may be less severe than with codeine); 
hallucinations, confusion and convulsions, as well 
as cases of drug dependence and withdrawal, 
have been reported with tramadol at therapeutic 
doses. The Committee on Safety of Medicines 
(CSM) advises that treatment with tramadol should 
be short-term and intermittent, and caution is 
required with patients with a history of addiction 
or dependence. Caution is also required with 
patients with a history of seizures and those taking 
drugs that lower the seizure threshold. Tramadol 
has a more problematic profile than other weak 
opioids because of its additional activity on other 
receptors which cause enhanced risk of withdrawal 
effects. It is no more effective and may be less 
suitable for use in the prison population and it 
should only be prescribed after a clinician has 
considered alternative analgesia and weighed risks 
of the prescription in terms of safety within the 
environment and the diversion potential into the 
illicit market. Specific establishments, through their 
medicines management committees may take a 
view that tramadol is not appropriate for use within 
a particular environment. 
Despite these considerations clinicians 
may encounter situations where a patient is 
inappropriately asking for opiates or situations 
where an existing opiate prescription could be 
being diverted to the wider prison population. In 
situations such as this it is advised that voluntary 
clinical urine drug testing using a detailed hospital 
laboratory analysis is undertaken. Where this is 
not possible Point-of-Care testing (POCT) kits for 
Tramadol, Buprenorphine, Methadone and other 
illicit drugs are available and can be used as an 
alternative means of checking for compliance.  
Tramadol will not be detected by these tests for 
‘opiates’.
The observation histories of third parties such as 
wing officers, nurses and gymnasium instructors 
may also be considered when making a balanced 
decision as to the continuance of an opiate 
analgesia prescription in the context of reported 
pain or impaired function where there is clinical 
doubt about the use and indication for an opiate 
analgesic, without compromising a patient’s 
confidentiality. This can allow for a more objective 
assessment of function and improvement than that 
provided by the patient alone.
In general, the management of pain within a secure 
environment should follow the same principles as 
the management of pain within the community. 
It should follow a stepwise approach in line with 
the World Health Organisation analgesic ladder 
model. It is only the medications and in some 
circumstances the formulations that may need a 
specific approach. 
Nefopam is a non-opioid centrally-acting analgesic 
for moderate pain. The evidence base is limited, 
however it may have a use where other non-opioid 
analgesics are ineffective, but sympathomimetic 
and antimuscarinic side effects may be a problem.
The value of complementary therapies should 
be emphasised and these, where available, may 
produce analgesic sparing effects.
It should be recognised that some patients may 
become depressed as a result of imprisonment 
with a corresponding reduction in their pain 
threshold. Complementary programmes and self-
help courses which have a holistic approach with 
self empowerment as a substantial part of the 
therapy may be particularly helpful. Therapists may 
be available in prisons to help with pain relief and 
lifestyle changes.
Cyclizine should be avoided in patients who use 
opiates illicitly due to well reported hallucinatory 
symptoms.
The management of palliative care in prisons is a 
rapidly developing area which presents important 
considerations for prison health care teams 
and prisons themselves. This guidance does 
not consider the specific issues pertaining to 
prescribing in palliative care within a prison.
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Opiates and other controlled drugs which are highly toxic in overdose should be carefully stored in prisons 
in line with Home Office regulations. Prisoners have died in certain situations having obtained the keys to the 
prison drug cupboard.
References: 
Committee on the Safety of Medicines (CSM)/ Medicines Control Agency (MCA). Current Problems in  
Pharmacovigilance 1996; 22: 9-12 (October). 
http://wwwmhra.gov.uk/Publications/Safetyguidance/CurrentProblemsinPharmacovigilance/CON007485 
[accessed 01 July 2011].
National Prescribing Centre (NPC). The withdrawal of co-proxamol: alternative analgesics for mild to moderate 
pain. Merec Bulletin 2006; 16(4) 
http://wwwnpc.co.uk/merec/pain/otherback/resources/merec_bulletin_vol16_no4.pdf 
[accessed 01 July 2011].
National Prescribing Centre (NPC). The use of oral analgesics in primary care. Merec Bulletin 2000; 11(1) 
http://www.npc.co.uk/merec/pain/otherback/resources/merec_bulletin_vol11_no1.pdf 
[accessed 01 July 2011].
World Health Organisation (WHO). Pain Ladder. 
http://www.who.int/cancer/palliative/painladder/en/ [accessed 04 July 2011].
Patient.co.uk. Analgesic ladder. 
http://www.patient.co.uk/doctor/Pain-and-Pain-Relief-(Analgesics).htm [accessed 04 July 2011].
Medication Place in therapy Environmental considerations Category
Paracetamol In accordance with the 
analgesic ladder.
Has an association with deliberate self 
harm by overdose which should be 
considered in patients at risk of self harm. 
Abuse potential low. Can be purchased 
over the counter in many prisons.
NSAIDS
Ibuprofen, 
Naproxen
In accordance with the 
analgesic ladder.
Nil of note. Can be dangerous in 
overdose. Risks of gastrointestinal 
ulceration and bleeding.
Nefopam Consider before opiate 
analgesia in selected 
individuals where other 
non-opioid analgesics 
ineffective. Limited 
evidence base of 
effectiveness.
Codeine Short duration use in 
patients who do not have 
opiate addiction problems.
Special care in patients with substance 
misuse histories.
Consider dispersible/ effervescent 
preparation with ‘co’ preparations.
Tramadol Consider after 
Paracetamol, NSAIDs, 
Nefopam and adjuvants in 
selected individuals
(see notes above).
Special consideration in patients with 
substance misuse histories. May be 
considered as a ‘red’ medication in  
some establishments.
 
Strong opiates:
Morphine, 
Fentanyl
Strong opiates are 
indicated in severe pain. 
They should be prescribed 
when indicated.
The prescribing of strong opiates to 
vulnerable, sometimes debilitated 
patients places them at risk of bullying. 
When prescribed this should be as part 
of a comprehensive treatment plan which 
also encompasses specific security 
concerns.
Dihydrocodeine Avoid in patients with 
substance misuse  
histories.
Special consideration in patients with 
substance misuse histories (with caution 
some prisons may consider this an 
amber medication).
Pethidine Very limited indications  
for Pethidine.
Strong opiates in tablet form present a 
significant risk of abuse.
Fentanyl 
‘lollipop’
Generally not appropriate
Consider other options.
Significant diversion potential.
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The international association 
for the study of pain defines 
neuropathic pain as “pain arising 
as a direct consequence of a 
lesion or disease affecting the 
somatosensory system”. Common 
examples of neuropathic pain 
syndromes are post-herpetic 
neuralgia, diabetic neuropathy, 
nerve entrapment syndromes, 
phantom limb pain, spinal cord 
injury, prolapsed disc, stroke, 
Multiple Sclerosis and Parkinson’s 
disease.
There is no standard diagnostic 
procedure for diagnosing neuropathic 
pain. The essential elements of 
the process are to identify painful 
symptoms, altered sensation and 
a clinical history that all match a 
neuro-anatomical or dermatomal 
pattern. Examination should identify 
altered sensation in the painful area. 
Numbness is often present in the 
dermatomal area and exaggerated 
painful response to pinprick testing.  
Medication Place in therapy Environmental considerations Category
Amitriptyline 
(also 
Nortriptyline 
and other 
TCAs)
First line
Advantage of once daily 
dosing (Unlicensed 
indication).
TCAs have significant commodity value 
as a result of their sedative effects. 
They are dangerous in overdose 
but risk can be lessened by closely 
supervised consumption.
Duloxetine Minimal abuse potential.
Has a licence for use in diabetic 
neuropathy and may be beneficial in 
other forms of neuropathy.
Gabapentin Second or third line. Recognised abuse potential. 
Special consideration in patients with 
substance misuse histories.
Pregabalin Second or third line. Well recognised abuse potential. 
Special consideration in patients with 
substance misuse histories.
Neuropathic Pain
In the prison setting, pregabalin and gabapentin are highly sought 
after because of their use in enhancing the effects of opiates and 
their own inherent abuse potential. In NICE guidance CG 96, 
gabapentin is not recommended for primary care prescribing but its 
use remains common and it is a licensed indication.  
Some of the difficulties with the treatment of neuropathic pain arise 
from inappropriate use of neuropathic analgesia for non neuropathic 
conditions or from sub optimal assessment by the initiating clinician 
leading to unnecessary prescribing.
As with analgesia guidance, information obtained from wing, gym 
and healthcare staff may be helpful in determining an independent 
assessment of the patient’s mobility to differentiate from a desire to 
obtain medication for trading or illicit use.
There is no clinical indication for the use of gabapentin and 
pregabalin for non-specific mechanical back pain which is often 
encountered in patients in prisons. Such prescribing causes 
problems for clinicians  trying to withdraw an inappropriately 
prescribed drug in a different establishment. In this clinical situation 
physical and complementary therapies such as physiotherapy or 
remedial gym should be considered.
Furthermore, if patients are referred for a specialist opinion GPs 
should be aware of the importance of providing an appropriate 
history of addictive behaviour in patients referred to pain clinics who 
are at risk of being prescribed these drugs inappropriately.
Second Line treatments
If pain reduction is not satisfactory with first 
line treatment at the maximum dose, consider 
combination or alternative therapy and re consider 
the primary diagnosis.
Third line treatment
•    If pain reduction is not satisfactory with second 
line treatment, refer to a pain specialist.
•    While waiting for the consultant opinion, 
consider oral opiate in combination with the 
second line treatment or as a replacement for 
the second line therapy. (Strong opiates should 
generally not be initiated by a primary care 
doctor in these circumstances).
Consider topical lidocaine for localised pain, 
however, this is only licensed for post-herpetic 
neuralgia.
It cannot be overstated that in prisons, the 
appropriate assessment of neuropathic pain is 
fundamental in the prescription of any analgesia 
as a comprehensive assessment will reduce 
inappropriate prescribing. The prescriber should 
be aware that a proportion of prisoners have been 
known to fabricate symptoms of neuropathic pain 
to gain access to these drugs and that they may 
have a comprehensive knowledge of the relevant 
signs and symptoms.
If illicit drug use is suspected or non-concordance 
or diversion possible a detailed urine drug screen is 
recommended.
References:
Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain. British Medical Journal 2009; 
339:b3002 (12 August) http://www.bmj.com/content/339/bmj.b3002.extract [accessed 01 July 2011].
Tan T, Barry P, Reken S, Baker M. Pharmacological management of neuropathic pain in non-specialist settings: 
summary of NICE guidance. British Medical Journal 2010; 340: c1079 (4 March 2010) http://www.bmj.com/
content/340/bmj.c1079.full [accessed 01 July 2011].
Resources:
NICE. Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist 
settings NICE clinical guideline CG96. London: NICE,  2010. http://www.nice.org.uk/guidance/CG96 
[accessed 01 July 2011].
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Depression
In assessing depression, in 
addition to clinical judgment, 
the use of standardised 
assessment tools may be of 
value. Antidepressant medication 
should be considered in moderate 
or severe depression. Previous 
treatment failure or success should 
be considered when considering 
which antidepressant medication 
to use. Where an antidepressant 
is not advocated for general use 
within a secure environment, an 
alternative medication with a more 
acceptable safety profile and 
lower abuse potential should be 
considered after an appropriate 
washout period where this is 
necessary.
Consider psychological therapies at all stages of depressive 
illness. Prisons should have good access to mental heath services 
and these resources should be used in patients presenting with 
depression.
When treating depression within prisons clinicians should be aware of 
the reported link between suicidal risk, depression and antidepressant 
therapy. Young adults and patients with a history of suicidal behaviour 
are particularly at risk and where necessary patients should be 
monitored closely for suicidal behaviour. The prison process of 
ACCT (Assessment, Care in Custody and Teamwork) may be 
valuable in this respect, and a joint approach between custody and 
healthcare staff is best practice. When considering suicidal risk in 
initiating antidepressants clinicians should also be aware that juvenile 
depression is itself a strong risk factor for both attempted and 
completed suicide, and that any decision to use antidepressants 
needs to balance the known risk of increased suicidality secondary to 
a depressive disorder against the apparent increased risk that may be 
attributed to the use of an antidepressant itself. 
The potential for abuse is linked to experience from the environment, 
known euphoric side effects and known sedating side effects. 
Where information is limited class effect is inferred.
When prescribing in a secure environment clinicians should be 
aware of the following points;
1.   When prescribed preference should be given to 
orodisperable formulation.
2.   BNF 60 September 2010 states ‘There is little to choose 
between the different classes of antidepressant drugs 
in terms of efficacy, so choice should be based on the 
individual patient’s requirements, including the presence 
of concomitant disease, existing therapy, suicide risk 
and previous response to antidepressant therapy. SSRIs 
are better tolerated and are safer in overdose than other 
classes of antidepressants and should be considered 
first-line for treating depression’.
3.   When augmentation with neuroleptics is being 
considered, it should normally only be considered 
by a psychiatrist or in liaison with a psychiatrist. 
Augmentation with buspirone is appropriate by primary 
care doctors with appropriate training and experience.
4.   Where the usual maximum BNF stated dose, given ‘In Possession’ for one week or longer, 
ingested in an act of self harm in a 70kg individual should result in a hospital admission as 
recommended by Toxbase, then the risk of In Possession provision should be specifically 
considered in any prescribing decision. This consideration is separate to the risk inherent in abuse 
and is not covered by PSO 3550 and PSI 45/2010. Individual policy regarding which medications 
can be kept in possession should be determined at establishment level in conjunction with the 
medicines management committee. It should reflect the population which the prison confines and 
allow for exceptions beyond the guidance stated above.
5.   Mirtazapine: Although mirtazapine use may be appropriate within a secure environment, any   
prescribing decision should take into account the medication’s links with substance misuse where 
it may be taken simply as a form of night sedation. As a result of the sedation caused by the use 
of mirtazapine, it is frequently requested by name by patients. It has definite potential for diversion 
and patients in receipt of mirtazapine may be subject to bullying. All these potential pitfalls should 
be considered in any prescribing decision. When prescribing is considered appropriate it should 
prescribed in an orodispersible form only. Urine drug testing should be considered to ensure 
compliance and the absence of illicit opiates. It should only be prescribed second or third line in 
major depression. Morning administration may reduce its popularity.
Medication Place in therapy Environmental considerations1 Category
Fluoxetine 1st line in depression - 
(Caution in epilepsy, 
Cardiac disease, Diabetes 
mellitus).
Bulimia nervosa, OCD.
Euphoria is a recognised side effect, but 
few reports of significant abuse.
Possible increase in suicidal ideation after 
initiation.
Available in a liquid formulation.
Citalopram 1st line in depression 
(Caution in epilepsy, 
Cardiac disease, Diabetes 
mellitus).
Panic disorder.
Euphoria is a recognised side effect, but 
no reports of significant abuse though 
less alerting than Fluoxetine.
Available in a liquid formulation.
Adults who have ingested 3mg/kg  
should be referred to hospital.
Paroxetine 2nd line in major 
depression OCD, PTSD, 
Panic disorder.
Low potential for abuse.
Available in liquid formulation
Symptoms of toxicity may be delayed 
as absorption is slow. Ingestion of 100 
-800mg have resulted in only minor 
symptoms.
Adults who have ingested 3mg/kg 
should be referred to hospital.
Recognised problems withdrawal.
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Escitalopram 2nd line in depression 
(Caution in epilepsy, 
Cardiac disease, Diabetes 
mellitus).
Panic disorder, GAD, social 
anxiety disorder.
Available in a liquid formulation
Little information is currently available 
but toxicity is expected to be similar to 
Citalopram.
Sertraline 2nd line in depression
(Consider 1st line post MI 
and epilepsy).
OCD
PTSD 
Low potential for abuse.
Trazodone 2nd line in depression Sedation is typical, therefore diversion 
and trading is likely.
Available in a liquid formulation
Doses of 2-3g have caused convulsions 
and respiratory arrest.
Death has been recorded after ingestion 
of 4.5g.
Mirtazapine 2nd or 3rd line in Major 
depression ONLY
Sedation is typical, therefore diversion 
and trading is likely and has been widely 
reported in prisons.
IT SHOULD NOT BE PRESCRIBED  
AS A SLEEPING TABLET 
Available in orodispersible form
Less toxic in overdose than other 
antidepressants. NO serious adverse 
events other than sedation and slight 
tachycardia reported.
Venlafaxine 2nd line Major depression
GAD
Seizures are common after ingestion of 
1.5g but have been documented with 
ingestion of 375mg.
Death has occurred at ingested dose of 
8.4g.
Amitriptyline Generally should not be 
used as an antidepressant.
Lower doses may be 
considered in neuropathic 
pain (unlicensed) or 
migraine prophylaxis 
(unlicensed) At lower 
doses Amitriptyline may be 
considered AMBER.
Patients should be offered alternative 
treatment
Tricyclic antidepressants are very toxic by 
ingestion. Normally ingestion of 15 mg/
kg would be expected to result in serious, 
potentially life-threatening symptoms.
Fatalities have occurred at doses >15 
mg/kg.
Dosulepin Depression Patient’s should be offered alternative 
treatment
Dosulepin is more toxic than other 
TCAs and has a mean dose causing 
convulsions of 1.9g compared to 3.0g for 
other TCAs.
May induce life threatening cardiac 
arrhythmias.
References: 
Marttunen MJ, Henriksson MM, Isometsä ET, 
Heikkinen ME, Aro HM, Lönnqvist JK. 
Completed suicide among adolescents with no 
diagnosable psychiatric disorder. 
Adolescence 1998; 33(131): 669-81 (Fall) 
http://findarticles.com/p/articles/mi_m2248/
is_131_33/ai_65352555/ [accessed 01 July 2011].
Resources:
National Poisons Information Service. Toxbase. The 
primary clinical toxicology database of the National 
Poisons Information Service.  
http://www.toxbase.org/ [accessed 04 July 2011].
Trivedi MH et al. Medication augmentation after 
the failure of SSRIs for depression. N Engl J Med 
2006;354:1243-52. 
http://www.nejm.org/doi/full/10.1056/
NEJMoa052964 [accessed 20 July 2011].
PHQ9 and HAD
http://www.psycho-oncology.info/PHQ9_
depression.pdf [accessed 05 July 2011].
PRIME-MD® Patient Health Questionnaire © 1999, 
Pfizer Inc.Reproduced with permission. Copyright 
© August 2003 Caremark.
http://www.gpnotebook.co.uk/simplepage.
cfm?ID=x20090201195702749131 [accessed 05 
July 2011]. 
Developed by Drs. Robert L. Spitzer, Janet B.W. 
Williams, Kurt Kroenke and colleagues, with an 
educational grant from Pfizer Inc. No permission 
required to reproduce, translate, display or 
distribute.
Hospital Anxiety Depression Scale 
(HADS)
http://www.scireproject.com/outcome-measures/
hospital-anxiety-and-depression-scale-hads  
[accessed 05 July 2011].
Generalised Anxiety Disorder (GAD)
http://www.ncbi.nlm.nih.gov/pubmedhealth/
PMH0001915/ [accessed 05 July 2011].
GAD-7 Questionnaire
http://www.patient.co.uk/doctor/Generalised-Anxi-
ety-Disorder-Assessment-(GAD-7).htm  
[accessed 05 July 2011].
Resources:
Depression. The treatment and management 
of depression In adults (updated edition) 
National Clinical Practice Guideline 90. National 
Collaborating Centre for Mental Health (NCCMH) 
commissioned by the National Institute for Health 
& Clinical Excellence (NICE). London: British 
Psychological Society and Royal College of 
Psychiatrists, 2010.  
http://www.nice.org.uk/nicemedia/
live/12329/45896/45896.pdf 
[accessed 01 July 2011].
Depression in children and young people: 
identification and management in primary, 
community and secondary care. National Clinical 
Practice Guideline Number 28. Developed By 
National Collaborating Centre For Mental Health 
(NCCMH). Commissioned by National Institute 
For Clinical Excellence (NICE). London: The British 
Psychological Society, 2005. 
http://www.nice.org.uk/nicemedia/
live/10970/29859/29859.pdf 
[accessed 01 July 2011].
Depression in adults with a chronic physical health 
problem: treatment and management. National 
Clinical Practice Guideline Number 91. National 
Collaborating Centre for Mental Health (NCCMH) 
commissioned by the National Institute for Health 
and Clinical Excellence (NICE). Depression in adults 
with a chronic physical health problem: full guideline 
FINAL DRAFT (October 2009).  
London: NICE, 2009. 
http://www.nice.org.uk/nicemedia/
live/12327/45913/45913.pdf 
[accessed 01 July 2011].
Taylor, David. The South London and Maudsley 
NHS Foundation Trust & Oxleas NHS Foundation 
Trust prescribing guidelines. 10th ed. / David 
Taylor, Carol Paton, Shitij Kapur. London : Informa 
Healthcare, 2009. 
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Epilepsy and Other 
Convulsive Conditions
Alcohol withdrawal, substance 
misuse, head injury and associated 
learning difficulty are common 
amongst the prison population, 
hence epilepsy is said to be more 
common amongst this group than 
in the general community. Research 
has not, however, confirmed this. 
The reported rate of epilepsy in a 
2002 meta-analysis was 0.7% in 
prison compared to 1% among 
young adult males in the UK1.
Antiepileptic medications can be 
desirable drugs of abuse as many 
of these drugs have sedative side 
effects. Doctors are understandably 
cautious about altering patient 
reported prescriptions. As with any 
prescribing in a secure environment, 
it is essential to seek conformation of 
any prescription before medication is 
continued on a repeat basis2. 
It is important to seek confirmation of a diagnosis of epilepsy for 
any prisoner claiming a history of epilepsy and where confirmation 
cannot be gained from the community general practitioner, 
neurological referral may be appropriate.
Whilst the desirability of abuse with these medications may 
suggest that prescribers only give these medications by supervised 
consumption the need to optimise concordance is important and 
to best prepare the patient for life in the community ‘in possession’ 
should not always be disallowed.
Patients may report being prescribed clonazepam for epilepsy to 
access a prescribed benzodiazepine. This is widely recognised 
in prisons and prescribers need to be aware of this. Clonazepam 
is difficult to identify in laboratory urine testing which further 
complicates the supervision of its use. It may be possible to 
discontinue clonazepam where there is no indication, after 
confirming that this is an inappropriate medication with relevant 
colleagues. Clonazepam should not be used as monotherapy and 
when presented with this scenario, a clinician should consider more 
appropriate management where epilepsy has been confirmed. 
Gabapentin and pregabalin (see also neuropathic pain) are also 
commonly requested by drug misusers for “nerve pain” resulting 
from old injuries as well as for epilepsy. These drugs also have 
benzodiazepine type anxiolytic effects which make them desirable to 
this group of patients. Their use in epilepsy is diminishing.
Epilepsy is not a condition that should be diagnosed and managed 
by a primary care doctor without recourse to a neurologist. Although 
a typical history may be suggestive of the diagnosis, the definitive 
diagnosis should be made by a neurologist after appropriate 
assessment. Unless fit frequency prevents this, it is good practice to 
allow the neurologist to advise on the initiation of specific treatment 
once the type of seizure has been elucidated and a diagnosis made.
 The Quality and Outcomes Framework (QOF) in the community 
requires review of epileptic patients’ medication and fit frequency 
and may prompt specialist review or form the framework by which 
a clinician could review the primary diagnosis and its management. 
Abrupt withdrawal of any anti epileptic drug prescribed for epilepsy 
should be avoided as this may precipitate rebound seizures. When 
withdrawal is undertaken, this process should be protracted and 
closely monitored.
Medication
Daily dose 
range
Prescribing notes and environmental 
considerations
Category
Carbamazepine 100mg-2g 
divided doses
Epilepsy, mood stabiliser and neuropathic pain. 
Use of modified release preparation significantly 
lessens the incidence of dose-related side effects.
Can cause blood, hepatic or skin disorders – 
monitoring for signs is essential. Use with caution in 
patients with history of haematological reaction to 
other drugs.
Available in liquid form
Sodium 
Valproate
600mg-2g Epilepsy and mood stabilisation (often given as 
Depakote - Semisodium Valproate). Monitor liver 
function in first 6 months.
Available in liquid form
Phenytoin 150-500mg Used less frequently since the introduction of less 
toxic alternatives. Skin, gum and blood abnormalities 
possible.
Available in liquid form
Lamotrigine 25-200mg Partial and generalised seizures – monotherapy and 
adjunctive. Unlicensed use in trigeminal neuralgia 
and bi-polar affective disorder. Serious skin reactions 
including Stevens Johnson syndrome. Also risk of 
serious blood disorders including DIC.
Available in dispersible tablets
Not widely abused.
Topirimate 25-800mg Monotherapy and adjunctive therapy. Migraine 
prophylaxis under specialist supervision. May cause 
suicidal ideation and nephrolithiasis.
Not widely abused.
Levetiracetam 250-3000mg Partial and generalised seizures – monotherapy and 
adjunctive. Side effects may include abdominal pain 
and vomiting. Rarely psychosis and suicidal ideation. 
Not widely abused.
Vigabatrin 1-3g Adjunctive treatment in partial / secondary 
generalisation. Visual field defects may develop
Available as a powder for dissolution in water
Not widely abused.
Gabapentin 100-2700mg Partial and generalised seizures – monotherapy and 
adjunctive. Neuropathic pain. Unlicensed use in 
trigeminal neuralgia. Extensively abused by drug users 
and high trading value4. 
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Pregabalin 25-600mg Partial and generalised seizures adjunctive treatment. 
Neuropathic pain. Generalised anxiety disorder. 
Extensively abused by drug users and very high 
trading value5. 
Clonazepam 0.5-8mg Status epilepticus, myoclonus and other forms of 
epilepsy. High diazepam equivalence. Extensively 
abused by drug users and very high trading value.
RED if being considered for monotherapy
Diazepam is not appropriate for maintenance monotherapy in epilepsy. 
Diazepam remains a popular drug of misuse and patients may fit when they withdraw from significant 
dependency. In this particular situation it is important to appropriately treat the diazepam dependence 
following substance misuse national guidance. If the patient has a seizure a secondary care opinion should be 
considered.
References:
Fazel S, Vassos E, Danesh J. Prevalence of epilepsy in prisoners: systematic review. British Medical Journal 
2002; 324: 1495 (22 June) 
http://www.bmj.com/content/324/7352/1495.full [accessed 01 July 2011].
HM Prison Service. Continuity of Healthcare for Prisoners. Prison Service Order (PSO) 3050, Paragraph 2.2. 
London: HMPS: 2006. 
http://www.hmprisonservice.gov.uk/resourcecentre/psispsos/listpsos/ [accessed 01 July 2011].
Joint Formulary Committee. British National Formulary. No. 58. London: British Medical Association and Royal 
Pharmaceutical Society of Great Britain, 2009.
Webb J. Gabapentin – another drug of misuse? British Columbia: Drug and Poison Information Centre, 2008. 
Originally published in BCPhA Tablet. 2008;17(3):12-3. 
http://www.dpic.org/article/professional/gabapentin-abuse  [accessed 01 July 2011].
Resources:
NICE. Newer drugs for epilepsy in Adults. Technology Appraisal Guidance 76. London: NICE, 2004. 
http://www.nice.org.uk/nicemedia/pdf/TA076fullguidance.pdf [accessed 01 July 2011].
Medication
Daily dose 
range
Prescribing notes and environmental 
considerations
Category
Anti-psychotic drugs are principally 
licensed to treat psychoses such 
as schizophrenia, hypomania 
and paranoid psychosis. They 
are also used to treat anxiety and 
aggressive behaviour. In some 
circumstances they are used 
in forensic psychiatry to treat 
personality disorder.
The original anti-psychotics, 
also known as neuroleptics 
and major tranquillisers include 
chlorpromazine, haloperidol and 
trifluoperazine. As well as being 
licensed for the treatment of 
psychoses they are also licensed 
for the treatment of anxiety and 
disturbed behaviour.
Psychoses
The newer atypical anti-psychotics include olanzapine, risperidone 
and quetiapine. They have a more acceptable side-effect profile with 
patients than the original drugs with fewer anti-cholinergic and extra-
pyramidal side-effects. They may however be more diabetogenic 
and new evidence is appearing regarding other side-effects. Robust 
monitoring should be in place for patients receiving antipsychotic 
medication. They are generally only licensed to treat psychotic 
conditions however their use in patients suffering from anxiety and 
personality disorder is increasing. It should be recognised however, 
that the use of anti-psychotic medication in personality disorder falls 
outside of NICE guidance.
It is recommended that the use of anti-psychotics should generally 
be the responsibility of the forensic psychiatrist. Although they may 
be prescribed by a primary care clinician with suitable training or 
experience, it is best practice, that in these circumstances, close 
liaison with a psychiatrist is undertaken and documented. 
Anti-psychotics should always be prescribed with caution and only 
by clinicians competent and experienced in their use. The older 
drugs have well recognised side-effects including anti-cholinergic 
symptoms such as dry mouth and constipation and extra-pyramidal 
problems causing movement disorders such as muscle stiffness and 
parkinsonism. Neuroleptic malignant syndrome is a rare but serious 
side-effect.
Atypical anti-psychotics are typically less sedating than the older 
drugs and cause fewer noticeable side-effects. There is increasing 
evidence that they can be diabetogenic. Clozapine which is used 
to treat intractable psychosis can cause significant haematological 
problems (hence the need for regular blood tests) although the 
incidence is rare.
Anti-psychotics are the treatment of choice for acutely psychotic 
prisoners. Each dose should be supervised as they can be 
dangerous in overdose. The patient’s mental state should be 
carefully assessed and closely monitored. They are not addictive 
drugs. They are useful in the management of disturbed patients. 
There are reports of fatal toxicity in high dose long term prescribing 
of the traditional drugs.
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Anti-psychotic medication may be diverted into 
the illicit economy of prisons. There is evidence 
that some patients snort or smoke quetiapine for 
its sedating effects. As such, as stated previously, 
all of these medicines should be prescribed with 
caution usually on a supervised consumption basis 
unless patient compliance and understanding 
of their condition is very good, and abuse of 
prescribed medication is not an issue in that 
particular establishment or on a particular wing, 
such as a resettlement wing. Here assessment of 
the patient’s ability to manage their own medication 
will be carried out with checking of concordance 
with in possession medication, prior to their 
managing their treatment on release into the 
community. As a group all of these medications are 
considered amber. Consideration should always be 
given to the formulation of the medication chosen 
with orodispersible and liquid preparations being 
effective in reducing diversion potential. Depot 
medication also provides a method of stopping 
diversion in patients with chronic psychoses, as 
well as improving compliance with treatment, and 
reducing risk in the wider prison population.
Because the reality is that psychiatrists may 
initiate anti-psychotic medicines but primary care 
prescribers usually rewrite the prescriptions, it 
is advisable that there is a written shared care 
protocol in place to ensure that the metabolic 
monitoring required for these antipsychotics (as 
per NICE guidelines) is embedded in the patient’s 
care plan and that the responsibility (primary 
or secondary care) for undertaking these tests 
and complying with the monitoring regime is 
defined. Then both prescribers can be confident 
in the arrangement and aware of their respective 
responsibilities.
Medication Place in therapy Environmental consideration Category
Anti psychotic 
medication
Generally these 
medications should be 
initiated by a psychiatrist, 
but when initiated by 
a primary care doctor, 
that doctor should have 
suitable experience or 
training and generally they 
should prescribe within 
licensed indications.
Clozapine has special monitoring 
requirements and must be prescribed by 
a forensic psychiatrist.
Registration with the manufacturer’s 
monitoring service is required for the 
prescriber and the dispensing pharmacy.
Resources:
National Collaborating Centre for Mental Health (NCCMH). Bipolar disorder. The management of bipolar 
disorder in adults, children and adolescents, in primary and secondary care. NICE Clinical Guideline 38. 
London: NICE, 2006. 
http://www.nice.org.uk/nicemedia/pdf/CG38niceguideline.pdf [accessed 01 July 2011].
National Collaborating Centre for Mental Health (NCCMH). Schizophrenia: Core interventions in the treatment 
and management of schizophrenia in adults in primary and secondary care NICE clinical guideline 82. London: 
British Psychological Society and The Royal College of Psychiatrists, 2010. 
http://www.nice.org.uk/nicemedia/live/11786/43607/43607.pdf [accessed 01 July 2011].
Clozapine monitoring guidelines  
http://www.mylan-clozapine.com/updatedguidelines.html [accessed 04 July 2011].
Continuation of 
treatment:
ADHD is a persisting disorder. Of 
the young people with sustained 
diagnosis, most will go on to have 
significant difficulties in adulthood, 
which may include continuing 
ADHD (NICE 2008). Some adults 
will therefore arrive in prison with 
current treatment of this disorder.
Attention Deficit 
Hyperactivity Disorder 
(ADHD)
This will usually be an amphetamine such as methylphenidate 
which is the first line of treatment in adults with ADHD (NICE 2008). 
Amphetamines can be and are abused within prison but in the 
case of ADHD these prescriptions should be continued without 
interruption with confirmation from the community prescriber being 
sought as a matter of urgency, as the trauma of arrest and arrival 
into custody is likely to have an adverse effect upon this condition. 
The medication should be continued as it is prescribed in the 
community initially, until the prisoner has settled and can enter into 
an informed discussion with regard to any review of treatment that 
might be indicated if the operational demands of the prison make 
the previous medication administration times impracticable in the 
longer term.  
Within the prison setting this medication will be given by supervised 
consumption as it has significant potential to be abused in the prison 
environment.
Identification and referral of adults with ADHD:
For adults with ADHD drug treatment should be the first line 
treatment (NICE 2008). Adults presenting with symptoms of ADHD 
in primary care or general adult psychiatric services who do not have 
a childhood diagnosis of ADHD should be referred for assessment 
by a mental health specialist trained in the diagnosis and treatment 
of ADHD (NICE 2008). It is not appropriate for primary care doctors 
to make an assumptive diagnosis and initiate a prescription of 
medication and where that diagnosis is in doubt good practice is the 
confirmation of the diagnosis. If the diagnosis cannot be confirmed 
then a psychiatrist should be consulted in the decision to continue 
or discontinue any medication. 
Adults who have previously been treated for ADHD as children or 
young people and present with symptoms suggestive of continuing 
ADHD should be referred to general adult psychiatric services for 
assessment (NICE 2008). In cases where ADHD falls outside of the 
purview of commissioned forensic in reach services, then individuals 
should still have access to general psychiatric services and advice 
should be sought from community services if necessary.
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ADHD and Substance Misuse:
Drug treatment for adults with ADHD who also misuse substances should only be prescribed by an 
appropriately qualified healthcare professional with expertise in managing both ADHD and substance misuse. 
For adults with ADHD and drug or alcohol addiction disorders there should be close liaison between the 
professional treating the person’s ADHD and an addiction specialist (NICE 2008).
Medication Place in therapy Environmental considerations Category
Methylphenidate Specialist initiation Significant abuse potential
Atomoxetine Specialist initiation Significant abuse potential
Dexamfetamine Specialist initiation Significant abuse potential
Resources
NICE. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in 
children and adolescents. Technology Appraisal 98 (Review of Technology Appraisal 13). London: NICE, 2006. 
http://www.nice.org.uk/nicemedia/live/11572/33222/33222.pdf [accessed 01 July 2011].
Benzodiazepines are highly 
efficacious in the short term 
treatment (two weeks or less) 
of anxiety and insomnia and in 
managing acute psychosis. When 
compared to their predecessors 
the barbiturates, they have an 
improved safety profile as they 
have a wider therapeutic window. 
They are drugs of very high 
abuse potential and as a class of 
medication they have significant 
potential to induce dependency. 
Unfortunately some patients 
quickly become dependent 
upon benzodiazepines and 
experience uncomfortable physical 
and psychological withdrawal 
symptoms. The physical syndrome 
associated with withdrawal 
from long term benzodiazepine 
use may include depression, 
anxiety, psychosis, suicide, status 
epilepticus and may be fatal. For 
these reasons it is generally not 
acceptable to initiate treatment 
with benzodiazepines in patients 
and treat them for longer than two 
weeks. 
Benzodiazepines:  
Use in Anxiety and  
Other Conditions
Many patients became dependent upon these drugs in the 
community in the three decades following their introduction in the 
1960s before evidence emerged of their addictiveness and clinicians 
changed their prescribing practice. Many patients remain dependent 
upon them. Encouraging patients to stop taking them is difficult 
but remains appropriate. Slow reduction (over weeks and months) 
remains the treatment plan of choice in individuals without a severe 
current mental illness. Where a severe mental illness is present 
reduction may still be appropriate but should only be undertaken 
after liaison with a psychiatrist.  
Benzodiazepines are very popular among drug users. They are 
widely available in the community as they are widely prescribed and 
thus easily diverted for illicit use. They are also easily purchased via 
the internet. They are sedating drugs which give an initial euphoria 
followed by relaxation and sleep. They can synergise the effects 
of heroin, other opiates including methadone, and alcohol. When 
combined in a cocktail with other substances they have been 
implicated in fatal accidental overdose. Drug users typically take 
them in large quantities orally for their euphoric effect and it is not 
unusual for doses of 100mg of diazepam to be reportedly consumed 
on a daily basis. Historically they have been injected however this 
method of administration is believed to be less prevalent at present. 
Their availability illicitly in prison is less than in the community but 
they remain highly sought after within secure environments. As a 
result, the prison clinician is frequently asked to prescribe medication 
for reported anxiety and they should be constantly vigilant to 
the possibility of this presentation being a route to inappropriate 
benzodiazepine use.
Diazepam is commonly used by Forensic Medical Examiners 
(FMEs) to alleviate the agitation associated with heroin withdrawal in 
Police custody and for treatment of anxiety: a positive urine test for 
benzodiazepines for patients received from police custody should 
not be used as the sole indicator of dependency. Benzodiazepine 
dependent patients entering custody whose dependency is proven 
or suspected and supported by urine testing should be treated 
in accordance with guidelines by slow reduction1. Treatment of 
benzodiazepine dependent patients whose dependency has been 
established and where diversion is a risk should be with diazepam 
liquid. Dependency may not be present where patients use 
benzodiazepines intermittently or irregularly.
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Chlordiazepoxide is used to treat alcohol 
withdrawal. When an alcohol dependent patient 
enters custody they should be treated with a 
chlordiazepoxide detoxification regime over a 
suitable time period which is typically around 
one week for low dependence. Dose regimes 
and length of treatment are dependent on the 
assessment of dependency and monitoring of 
withdrawal in line with locally agreed evidence 
based protocols. Patients in treatment are still at 
risk of fitting and should be closely monitored.
All general practitioners including GPs who work 
in prisons should generally avoid prescribing 
benzodiazepines other than in special 
circumstances. They should not use them to treat 
insomnia. Occasional prescribing for debilitating 
anxiety or spasmodic back pain is recognised 
however within prisons it should be considered 
best practice to explore other treatments where 
appropriate first. An example of this would be 
the prescription of buspirone to treat anxiety that 
has not responded to a cognitive behavioural 
therapeutic approach. 
Benzodiazepines may be used in the very short 
term to treat acute distress from bereavement and 
in psychosis, though treatment with anti psychotic 
medication is preferred in psychotic patients. 
There is no indication for prescribing lorazepam 
on an ongoing basis. It is the most addictive 
benzodiazepine.
Clonazepam treatment is often requested by 
prisoners on the grounds that they have epilepsy 
for which it is a licensed adjuvant treatment (see 
section on epilepsy earlier in this guidance). It is 
however popular in non-epileptic patients who 
take it as a hypnotic and misuse it. It is crucial 
therefore that the prison General Practitioner 
confirms the diagnosis of epilepsy and its treatment 
with clonazepam prior to prescribing as misuse 
and inappropriate prescribing demands are well 
recognised within the prison population.
General Practitioners have a responsibility to 
limit benzodiazepine prescribing and reduce 
diversion and misuse. This is especially important 
in prisons where drug users will actively seek 
benzodiazepines for their euphoric, anxiolytic and 
hypnotic effect. They may be used as currency 
within the illicit economy of a prison and their 
presence in the illicit economy does lead to bullying 
and violence. 
When a clinician considers it appropriate to 
prescribe a benzodiazepine, they should be aware 
of the potential for paradoxical or disinhibitory 
reactions. These may include acute excitement, 
hyperactivity, increased anxiety, hostility and 
sometimes rage. In high risk patients these 
paradoxical reactions may be in the region of 10 
– 20% of patients. Those considered high risk of 
paradoxical reaction include patients with learning 
disorders, young patients and those individuals 
who have a history of aggression and poor impulse 
control.
Benzodiazepine use should usually be restricted 
to benzodiazepine and alcohol dependent patients 
treated under clear guidelines. They may also be 
used in florid psychosis when a forensic psychiatrist 
should be involved with treatment, some cases of 
epilepsy including the acute management of status 
epilepticus with rectal diazepam and end of life care 
(midazalom). 
Although not a benzodiazepine, buspirone 
may play a useful role in the management of 
anxiety. It displays less dependency potential 
than benzodiazepines. It should not be used 
for benzodiazepine withdrawal, but offers an 
appropriate method of augmenting the action of 
antidepressants and may be used appropriately by 
primary care doctors in this role. Propranolol also 
has a role in the treatment of anxiety within prisons. 
It is not subject to misuse and can be prescribed 
to reduce some of the physical symptoms of 
anxiety. It may therefore be considered to have a 
benzodiazepine sparing effect.
Medication Place in therapy Environmental consideration Category
Diazepam Usually in the form of a 
detoxification regime but 
exceptions do occur.
In patients with proven or suspect 
history of illicit use, diazepam should be 
prescribed as a liquid formulation where 
diversion is a risk.
Chlordiazepoxide Alcohol detoxification.
Lorazepam Rapid sedation in 
distressing anxiety.
Short term use only
(not to be used for maintenance).
Midazolam Terminal care. As an unlicensed medication buccal 
Midazolam may be used to treat an 
epileptic seizure. Clinicians should be 
aware of the ease of faking a seizure 
as a route to getting benzodiazepines 
administered.
Clonazepam Adjunct in epilepsy. Confirmation of prescription and 
diagnosis should be sought.
Sought after for it’s abuse potential.
Benzodiazepines insomnia.
References:
Department of Health. Clinical Management of Drug Dependence in the Adult Prison Setting including 
psychosocial treatment as a core part. London: Department of Health, 2006. 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/
dh_115004.pdf [accessed 01 July 2011].
Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. American Journal 
of Psychiatry 1985; 142(1): 98-100 
http://ajp.psychiatryonline.org/cgi/content/abstract/142/1/98 [accessed 01 July 2011].
Resources:
National Collaborating Centre for Mental Health and the Royal College of General Practitioners. Generalised 
anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary 
and community care (partial update). National Clinical Guideline 113. Commissioned by the National Institute 
for Health and Clinical Excellence (NICE). London: NICE, 2011. 
http://www.nice.org.uk/nicemedia/live/13314/52667/52667.pdf [accessed 04 July 2011].
Benzodiazepine refs 
NHS Grampian. Guidance for prescribing and withdrawal of benzodiazepines and hypnotics in general 
practice. Version 1. October 2006. Review date October 2008. http://www.nhsgrampian.org/grampianfoi/files/
Benzodiazepine_guidance_Octoberv6_2.pdf 
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Introduction:
Sleep problems are regularly 
presented to prison healthcare 
staff. The prevalence of substance 
misuse and alcohol dependency 
combined with the loss of 
autonomy and sedentary lifestyle in 
prison make this understandable. 
Drug misusers have a tendency to 
seek pharmacological remedies 
rather than psychosocial ones 
for insomnia. It can be difficult to 
dissuade them from this approach. 
NICE guidance states:
“When, after due consideration 
of the use of nonpharmacological 
measures, hypnotic drug therapy 
is considered appropriate for the 
management of severe insomnia 
interfering with normal daily life, 
it is recommended that hypnotics 
should be prescribed for short 
periods of time only, in strict 
accordance with their licensed 
indications.” (NICE 2004)1.
Insomnia
NICE recommends not substituting one drug for another if the first 
line drug is ineffective. Whilst short acting benzodiazepines are 
recommended as being most cost effective, these drugs are widely 
abused in prison settings and routine use is discouraged. 
One of the problems a clinician who works within prisons will 
experience when assessing insomnia is the expectations of the 
individual who has a history of drug and alcohol misuse. Sleep 
patterns may be acceptably normal from a clinical perspective but 
from the patient perspective, sleep latency and normal disruption 
of sleep is contrasting to their usual experience of sleep induced by 
illicit benzodiazepine use, heroin use and alcohol use. Education and 
the offering of realistic expectations can help in this scenario.
Patients within prisons do have justifiable requests for hypnotic 
medication though and not all requests for hypnotics are 
inappropriate. Significant life stresses may impact on sleep and this 
may affect daytime functioning. Before a court appearance or on 
receipt of a long sentence may both be justifiable scenarios in which 
a clinician could offer night sedation. In these circumstances there 
may be a reduction in the risk of deliberate self harm. Bereavement 
and the stress of release after a protracted period in custody could 
also justify prescribing a hypnotic. It is less justifiable to prescribe 
hypnotics for chronic insomnia and routinely for withdrawal 
symptomology during detoxification from illicit drug misuse although 
at the end of a reduction regime this may occasionally be justified 
for a very short period as the patient adjusts to the first few days of 
abstinence. Patients receiving treatment for Hepatitis C are often 
prescribed a short course of a hypnotic such as zopiclone for use 
around the time of their peg-interferon injection to assist in the 
treatment of insomnia.
Milky drinks may have a place in the management of sleep problems 
and are recommended as part of the Integrated Drug Treatment 
System clinical guidelines (DH 2006) for the first fourteen days of 
treatment. Prisons have offered this as part of a reduction in the 
routine prescribing of hypnotics for withdrawal management since 
2000 and generally report this intervention to have a positive effect 
and to be well received by the prisoners. 
The provision of lavender oil has also been used to good effect in 
some centres in the female estate.
A sleep diary may be requested from the patient. 
It is also possible within some prison settings for 
this reported sleep pattern to be confirmed with 
observation of the patient’s sleep pattern by prison 
night staff.  
Sleep hygiene should be discussed when a patient 
presents with uncomplicated insomnia. Although 
not fully transferable in practice to the prison 
setting, sleep hygiene recommendations still have 
a role and the effect of reducing caffeine intake, not 
exercising late at night etc., may be helpful.
The NHS Choices patient leaflet may be offered to 
inform the patient about the reasons for prescribing 
or not. It is also appropriate to adapt this leaflet to 
reflect the prevalence of learning difficulty within 
patients held within the prison estate.
Sedating antihistamines, benzodiazepines, Z drugs 
and melatonin are licensed for the short term 
management of insomnia.
One melatonin product is currently licensed for 
short term use in insomnia for patients over 55 
years of age. It is not widely used within prisons 
and because of this limited use there are currently 
no reports of misuse. If used routinely within a 
particular establishment, then misuse may follow 
and clinicians should be aware of this. As a recently 
licensed product, many local health communities 
will restrict the preparation to prescribing by 
consultants in secondary care and this should 
be taken into account as part of the prescribing 
decision process.
Recommended drugs:
Drug Dose Prescribing notes and environmental considerations Category
Melatonin Limited licence. Not known to be widely misused – See 
notes above.
Z drugs: 
Zopiclone, 
Zolpidem and 
Zaleplon
These can be used for short periods if there is a clear 
necessity for a hypnotic.
Zopiclone is the most widely used in the community. 
They may be diverted and do enter the illicit economy. 
Prescribe with caution in prisons.
Promethazine 25-50mg Traditionally used as a ‘safer’ hypnotic in prisons but 
widely abused in the community. Misusers report that 
anticholinergic antihistamines are used to boost opiate 
highs.
Sedation lasts up to 12 hours so likely hangover effect 
next morning with psychomotor impairment.
Hypnotic effect wears off after a few days.
Temazepam 10-20mg Generally the use of benzodiazepines remains 
discouraged within a prison environment. 
Temazepam and other benzodiazepines should not be 
chosen on cost grounds alone.
The choice of a benzodiazepine should be justified 
within the clinical notes and the time limited treatment 
plan should also be documented.
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Clinical treatment of Substance 
Misuse in prisons is detailed in 
Clinical Management of Drug 
Dependence in the Adult Prison 
Setting (DH 2006).
One of the main difficulties facing 
clinicians practising within a 
custodial setting is the potential for 
misuse of many of the medications 
prescribed for the management of 
substance misuse. None of these 
drugs can be given In Possession 
(PSO 3550 – Clinical Services 
for Substance Misusers and PSI 
45/2010 Integrated Drug Treatment 
System), and the timing of the 
administration of some of these 
drugs may need to be considered 
taking into account the operational 
demands of the prison, although 
there is a need to ensure that the 
treatment needs themselves are 
not compromised.
Substance Misuse
Methadone is recommended as first-line treatment in prisons for the 
treatment of opiate substance misuse in line with the evidence base 
and guidance (DH 2006; NICE 2007). Buprenorphine is a treatment 
option for some patients particularly those who come into prison 
already on an existing community prescription. 
The perceived advantages of prescribing Suboxone over 
buprenorphine are mainly in community models to prevent misuse or 
accidental overdose in those patients who do not have supervised 
consumption models of care, to prevent harm from injecting or 
snorting buprenorphine or accidental overdose by another person. 
In prison all administration is by supervised consumption, so there 
is no clinical rationale for using Suboxone over plain buprenorphine. 
There are no Royal Pharmaceutical Society guidelines/advice for 
crushing Suboxone as there is for buprenorphine. The authors are 
unaware of any studies investigating the possible loss of efficacy 
of Suboxone by crushing which have vindicated this method of 
administration.
In addition to the clinical matters above, the practicalities in a prison 
are such that there is not the time to safely administer Suboxone to 
a large number of patients by supervised consumption. Any such 
administration by crushing would therefore not only be ‘off licence’ 
but could also impact on healthcare professionals’ indemnity 
insurance and lead to the possibility of exposure of litigation with 
regard to efficacy. Buprenorphine misuse is widespread, both in the 
community and in prisons. Misuse has been found to be prevalent 
in prisons where it is not prescribed, as it comes into prison via 
the usual illicit supply chains. Changing to Suboxone rather than 
Buprenorphine is not likely to reduce illicit use within the prison.
In all cases of prescribing for opiate substitution, the dialogue is with 
the prescriber and patient as to the best clinical treatment within 
the current treatment guidelines and protocols, and the prescriber 
should be aware of all of the pressures to prescribe particular drugs.
Where prisoners are received into prison already stabilised on a 
treatment regime initiated in the community then it is good practice 
to maintain that treatment regime for remand prisoners or those with 
a short sentence (in accordance with National Treatment Agency 
guidelines).
Opiate substitute prescribing forms a large part of the treatment 
for substance misusers in prison. Whilst there needs to be an 
equivalence of treatment options comparable to the community, it is 
also important to acknowledge that illicit drugs may be less readily 
available in a prison environment and that this should be taken into 
account when making clinical decisions about the prescribing of 
substitute medication for opiate users in prison.
References:
NICE. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. 
Paragraph 1.1. Technology Appraisal 77. London: NICE, 2004.  
http://www.nice.org.uk/nicemedia/pdf/TA077fullguidance.pdf [accessed 04 July 2011].
Department of Health. Clinical Management of Drug Dependence in the Adult Prison Setting including 
psychosocial treatment as a core part. London: Department of Health, 2006. 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/
dh_115004.pdf [accessed 04 July 2011].
Joint Formulary Committee. British National Formulary. 60 ed. London: British Medical Association and Royal 
Pharmaceutical Society of Great Britain; 2010. 
http://www.nhs.uk/Conditions/Insomnia/Pages/Treatment.aspx [accessed 7 February 2010].
Insomnia – treatment.  
http://www.nhs.uk/Conditions/Insomnia/Pages/Treatment.aspx [accessed 04 July 2011].
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Doctors working in prisons should also be aware of 
the demand for codeine based analgesics including 
tramadol within a prison as described within the 
previous sections above. They should ensure that 
these are not prescribed to maintain a substance 
misuse habit and that where necessary the patient 
is assessed for an opiate dependency if this is 
suspected. Opiates are generally unsuitable for use 
in patients with a history of substance misuse for 
the treatment of mild to moderate pain. It is vitality 
important that the fact that the patient is being 
treated for, or has a history of opiate dependence, 
should be made known to all other prescribers, 
including dentists so that appropriate pain 
management may be used.
References:
Department of Health. Clinical Management of Drug Dependence in the Adult Prison Setting including 
psychosocial treatment as a core part. London: Department of Health, 2006. 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/
dh_115004.pdf [accessed 04 July 2011].
Resources:
NICE. Methadone and buprenorphine for managing opioid dependence. NICE technology appraisal guidance 
114. London: NICE,  2007. 
http://www.nice.org.uk/nicemedia/live/11606/33833/33833.pdf [accessed 04 July 2011].
NICE. Naltrexone for managing opioid dependence. NICE technology appraisal guidance 115.  
London: NICE,  2007.  
http://www.nice.org.uk/nicemedia/live/11604/33814/33814.pdf [accessed 04 July 2011].
National Collaborating Centre for Mental Health. Opioid detoxification. National Clinical Practice Guideline 
Number 52 commissioned by the National Institute for Health & Clinical Excellence (NICE). London: The British 
Psychological Society and The Royal College of Psychiatrists, 2008. http://www.nice.org.uk/nicemedia/
live/11813/35999/35999.pdf [accessed 04 July 2011].
GPs play an important part in 
managing patients in a palliative 
care context. An ageing prison 
population necessitates the 
increasing application of these 
skills to the prison setting. Strong 
opiate medication is often used in 
palliative care patients with cancer.
Palliative Care
Injectable opiates and midazolam are useful medicines for patients 
in the terminal stage of their illness. Prison health care teams should 
have guidelines in place for the safe and compassionate treatment 
of patients who need end of life care. The team should be aware 
of and deploy the Gold Standards Framework and Liverpool 
Care Pathway when appropriate. The security implications of 
administering powerful opiates and benzodiazepines in the prison 
must be carefully evaluated. 
Reference:
Department of Health. End of Life Care Strategy: quality markers 
and measures for end of life care. London:  
Department of Health, 2009.  
http://www.londonhp.nhs.uk/wp-content/uploads/2011/03/DH-
EOLC-strategy.pdf [accessed 04 July 2011].
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